4[6]Fisher B,Costantino JP,Wickerham DL,et al.Tamoxifen for prevention of breast cancer:Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst,1998,90(18):1371.
6[8]Silvana Martino.Continuing outcomes relevant to Evista:Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.J Natl Cancer Inst,2004,96:1731.
7[9]Baum M,Buzdar A,Cuzick J,et al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial.Lancet,2002,359(9324):2131-2139.
8[10]Goss PE,Ingle JN,Martino S,et al.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early2 stage breast cancer.N Engl J Med,2003,349(19):1793-1802.
9[11]Coombes RC,Hall E,Gibson LJ,et al.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med,2004,350(11):1081-1092.
10[12]Veronesi U,De Palo G,Marubini E,et al.Randomized trial of fenretinide to p revent second breast malignancy in women with early breast cancer.J Natl Cancer Inst,1999,91:1847.
2[1]Fisher B,Costantino JP,Wickerham DL,et al.Tamoxifen for prevention of breast cancer:Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J National Cancer Ins,2005,97 (22):1652
3[2]Fisher B,Costantino JP,Wickerham DL,et al.Tamoxifen for prevention of breast cancer:Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst,1998,90 (18):1371
4[3]Cauley JA,Norton L,Lippman ME,et al.Continued breast cancer risks reduction in postmenopausal women treatment with raloxifene:42year results from the MORE trial.Multiple outcome of raloxifene evaluation.Breast Cancer Res Treat,2001,65 (2):125
5[4]Silvana Martino.Continuing outcomes relevant to Evista:Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.J Natl Cancer Inst,2004; 96:1731
6[5]Land SR,Wickerham DL.Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention:The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA,2006,295(23):2742
7[6]Goss PE,Ingle JN,Martino S,et al.A randomized trial of letrozole inpostmenopausal women after five years of tamoxifen therapy for early 2 stage breast cancer.N Engl J Med,2003,349 (19):1793
8[7]Coombes RC,Hall E,Gibson LJ,et al.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med,2004,350 (11):1081
9[8]ATAC Trialists' Group.Results of the ATAC (Arimidex,Tamoxifen,Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.Lancet,2005,365:60
10[9]Harris RE,Beebe-Donk J,ALshafie CA.Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.BMC Cancer,2006,6:27
